JP2022035920A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022035920A5 JP2022035920A5 JP2020187268A JP2020187268A JP2022035920A5 JP 2022035920 A5 JP2022035920 A5 JP 2022035920A5 JP 2020187268 A JP2020187268 A JP 2020187268A JP 2020187268 A JP2020187268 A JP 2020187268A JP 2022035920 A5 JP2022035920 A5 JP 2022035920A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- combination
- patient
- protein
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063067388P | 2020-08-19 | 2020-08-19 | |
| US63/067,388 | 2020-08-19 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022035920A JP2022035920A (ja) | 2022-03-04 |
| JP2022035920A5 true JP2022035920A5 (enExample) | 2023-11-17 |
| JP7657041B2 JP7657041B2 (ja) | 2025-04-04 |
Family
ID=77666491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020187268A Active JP7657041B2 (ja) | 2020-08-19 | 2020-11-10 | 併用療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20220073888A1 (enExample) |
| EP (1) | EP4199955A1 (enExample) |
| JP (1) | JP7657041B2 (enExample) |
| KR (1) | KR20220022828A (enExample) |
| CN (1) | CN116096874A (enExample) |
| AU (1) | AU2020267165B2 (enExample) |
| CA (1) | CA3098818A1 (enExample) |
| TW (1) | TW202207937A (enExample) |
| WO (1) | WO2022038191A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4608433A1 (en) | 2022-10-28 | 2025-09-03 | Astrazeneca AB | Recombinant apyrase protein for use in the treatment of an ischemic event at a dose of 40-240 mg |
| WO2025104274A1 (en) * | 2023-11-16 | 2025-05-22 | Hyloris Developments Sa | Ticagrelor iv for use in the prevention of thromboembolic events |
| WO2025104277A1 (en) * | 2023-11-16 | 2025-05-22 | Hyloris Developments Sa | Ticagrelor iv for use in the treatment, reduction or prevention of an ischemic event in a patient undergoing a percutaneous coronary intervention (pci) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7247300B1 (en) | 2002-11-07 | 2007-07-24 | Apt Therapeutics, Inc. | Therapeutic use of soluble CD39L3 |
| EP2133430B1 (en) | 2004-02-27 | 2014-12-17 | APT Therapeutics, Inc. | Design and therapeutic use of adpase enhanced apyrases |
| TWI482772B (zh) | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物 |
| WO2011088231A1 (en) * | 2010-01-13 | 2011-07-21 | Apt Therapeutics, Inc. | Apyrase therapy for bleeding conditions |
| US8771683B2 (en) | 2010-01-13 | 2014-07-08 | Apt Therapeutics, Inc. | Therapeutic apyrase constructs, apyrase agents, and production methods |
| CN107595789B (zh) | 2016-04-21 | 2021-01-15 | 阿斯利康(瑞典)有限公司 | 口腔崩解片 |
-
2020
- 2020-11-10 CA CA3098818A patent/CA3098818A1/en active Pending
- 2020-11-10 AU AU2020267165A patent/AU2020267165B2/en active Active
- 2020-11-10 JP JP2020187268A patent/JP7657041B2/ja active Active
- 2020-11-11 KR KR1020200150157A patent/KR20220022828A/ko active Pending
- 2020-11-11 TW TW109139411A patent/TW202207937A/zh unknown
-
2021
- 2021-08-18 CN CN202180056616.9A patent/CN116096874A/zh active Pending
- 2021-08-18 WO PCT/EP2021/072954 patent/WO2022038191A1/en not_active Ceased
- 2021-08-18 EP EP21766429.1A patent/EP4199955A1/en active Pending
- 2021-08-18 US US17/405,670 patent/US20220073888A1/en not_active Abandoned
-
2023
- 2023-07-14 US US18/352,414 patent/US20240026318A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022035920A5 (enExample) | ||
| JP2019196370A5 (enExample) | ||
| US20250000933A1 (en) | Terlipressin compositions and their methods of use | |
| RU2010101892A (ru) | Гиалуронидаза и способ ее применения | |
| JP2005506345A5 (enExample) | ||
| WO2021037933A1 (en) | Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer | |
| JP2019507174A5 (enExample) | ||
| JP2007501806A5 (enExample) | ||
| JPWO2021123902A5 (enExample) | ||
| CA2516458C (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| JP2023510609A (ja) | Ｇｌｐ－１および／またはｇｌｐ－１類似体、ならびにインスリンおよび／またはインスリン類似体を含む併用療法 | |
| JPWO2022240688A5 (enExample) | ||
| EP4687946A1 (en) | Methods and uses for treating nausea and emesis | |
| CN102389564A (zh) | 用于治疗骨髓增生异常综合征的组合物和方法及用途 | |
| JP2021169472A5 (enExample) | ||
| Witika et al. | Clinical Applications of Long Acting Injectables: Systemic and Local Drug Delivery | |
| WO2020026102A1 (en) | Combination therapy for treating cancer | |
| JPWO2022125598A5 (enExample) | ||
| Peyrin-Biroulet et al. | S2 Impact of Obefazimod Induction Therapy on Histologic and Combined Histologic and Endoscopic Outcomes in Patients With Moderately to Severely Active Ulcerative Colitis: Week 8 Results from the Phase 2b Induction Trial | |
| JPWO2021150559A5 (enExample) | ||
| CA2802176A1 (en) | Methods of mitigating effects of radiation and reducing the risk of systemic infection | |
| JPWO2021064618A5 (enExample) | ||
| JPWO2023172917A5 (enExample) | ||
| WO2013019220A1 (en) | Compositions and methods for treating myelodysplastic syndrome | |
| JPWO2022035752A5 (enExample) |